Capital raised by Dewpoint Therapeutics
1 Form D filing · first filed Sep 2025 · Boston, MA
President and Chief Executive Officer
Signatory on Dewpoint Therapeutics's Form D filings · $77.2M raised across 1
Ameet Nathwani is on file as President and Chief Executive Officer at Dewpoint Therapeutics in Boston, MA. Dewpoint Therapeutics has 1 Form D filing on record, $77.2M raised in total. Ameet Nathwani appears as a signatory on the company's filings.
LinkedIn profileA portfolio of small-molecule condensate modulators discovered on the ERSAi platform, led by DPTX3186, a beta-catenin condensate modulator in Phase 1/2 for gastric cancer with FDA fast track and orphan drug designations, alongside an oral MYC modulator enrolling patients in solid tumors and a TDP-43 development candidate for ALS.
